Drug intelligence / Profile preview

Tiaoshen Tongbi granules

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Tiaoshen Tongbi granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed for the treatment of nonspecific low back pain (NLBP), a condition often characterized in TCM as involving kidney deficiency and 'Bi' (obstruction) syndrome. The granules are a modern formulation of the Tiaoshen Tongbi decoction, intended to improve patient compliance and standardization. Clinical evaluation, such as the Phase 1 trial ChiCTR2400088757, focuses on its safety and efficacy in reducing pain and improving physical function when combined with core functional exercises.

Other names: Tiaoshen Tongbi Keli

Beyond the preview

Go deeper on Tiaoshen Tongbi granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaoshen Tongbi granules.

Explore the full profile